Clinical Benefits Th-302, A Tumor-Selective, Hypoxia-Activated Prodrug, And Gemcitabine In First-Line Pancreatic Cancer (Panc).Mitesh J. Borad,E. G. Chiorean,Julian R. Molina,A. C. Mita,Jeffrey R. Infante,W. R. Schelman,A. M. Traynor,G. Vlahovic,David S. Mendelson,S. G. ReddyJOURNAL OF CLINICAL ONCOLOGY(2011)引用 5|浏览14暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要